cloridrato de dexmedetomidina
volpharma distribuidora de produtos hospitalares e farmacÊuticos ltda - cloridrato de dexmedetomidina - hipnoticos
cloridrato de dexmedetomidina
antibiÓticos do brasil ltda - cloridrato de dexmedetomidina - hipnoticos
cloridrato de dexmedetomidina
aurobindo pharma indÚstria farmacÊutica limitada - cloridrato de dexmedetomidina - hipnoticos
cloridrato de dexmedetomidina
eurofarma laboratÓrios s.a. - cloridrato de dexmedetomidina - hipnoticos
cloridrato de dexmedetomidina
uniÃo quÍmica farmacÊutica nacional s/a - cloridrato de dexmedetomidina - hipnoticos
cloridrato de dexmedetomidina
cristÁlia produtos quÍmicos farmacÊuticos ltda. - cloridrato de dexmedetomidina - hipnoticos
cloridrato de dexmedetomidina
sanval comÉrcio e indÚstria ltda - cloridrato de dexmedetomidina - hipnoticos
cloridrato de dexmedetomidina
wyeth indÚstria farmacÊutica ltda - cloridrato de dexmedetomidina - hipnoticos
zenalpha
vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psicolepticos, hipnóticos e sedativos - cães - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triplo terapia de combinação), como adjuvante da dieta e exercício em pacientes inadequadamente controlados em sua máxima tolerada, a dose de metformina e uma sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.